Long-term real-world outcomes of first-line immunotherapy in non-small cell lung cancer – a population-based cohort study in Sweden
Real-world OS in Swedish patients receiving first-line PD-(L)1 inhibitor-based regimens was consistent with that observed in clinical trials. Moderate OS rates were observed in PS2, with limited sample sizes. Further research is needed in these patients, as well as in high PD-L1, given the slightly longer OS for combination therapy compared to monotherapy seen for NSQ.
Authors
- Stina Salomonsson (ORCID: https://orcid.org/0000-0002-1556-8075)
- Gunnar Wagenius (ORCID: https://orcid.org/0009-0002-9876-2160)
- Hans Brunnström (ORCID: https://orcid.org/0000-0001-7402-138X)
- Anders Vikström (ORCID: https://orcid.org/0000-0003-3549-3944)
- Goran Benčina (ORCID: https://orcid.org/0000-0001-6293-8211)
- Diana Chirovsky (ORCID: https://orcid.org/0000-0003-1641-1990)
- Anders Berglund (ORCID: https://orcid.org/0000-0003-3698-9861)
- Xiaohan Hu (ORCID: https://orcid.org/0000-0003-1765-306X)
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Karolinska University Hospital (SE)
- Lund University (SE)
- Karolinska Institutet (SE)
- Skåne University Hospital (SE)
- Linköping University Hospital (SE)
Publication Details
- Journal
- Acta Oncologica
- Published
- 2025-03-17
- DOI
- https://doi.org/10.2340/1651-226x.2025.42746
- Citations
- 3
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 3.14